Company news

Natera, Inc. news in 2023

Natera, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 28, 2023

Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test

December 26, 2023

Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA

December 20, 2023

Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents

December 10, 2023

Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

December 5, 2023

Natera Announces Real-World Data Collaboration with Merck

November 13, 2023

Natera Reports Third Quarter 2023 Financial Results

November 7, 2023

Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

November 7, 2023

Natera to Participate in November Investor Conferences

November 6, 2023

Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease

November 1, 2023

Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients

October 21, 2023

Natera to Report its Third Quarter 2023 Results on November 8

October 19, 2023

Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking

October 18, 2023

Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

October 15, 2023

New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early

October 3, 2023

Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

October 2, 2023

Natera Submits First PMA Module to the FDA for Signatera™

October 1, 2023

Natera Announces Senior Leadership Appointments

September 17, 2023

Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

September 13, 2023

Natera Announces Pricing of $250 Million Follow-On Offering

September 6, 2023

Natera Launches Proposed Follow-On Offering

September 5, 2023

Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage

August 15, 2023

Natera Reports Second Quarter 2023 Financial Results

August 2, 2023

Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference

August 1, 2023

Natera Files Patent Infringement Suit Against NeoGenomics

July 30, 2023

Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer

July 27, 2023

Natera to Report its Second Quarter 2023 Results on August 3rd

July 26, 2023

Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages

July 16, 2023

Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

June 5, 2023

Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection

June 3, 2023

New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types

May 29, 2023

Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits

May 14, 2023

Natera Reports First Quarter 2023 Financial Results

May 8, 2023

Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

May 7, 2023

Natera Announces First Quarter 2023 Earnings Conference Call

May 1, 2023

Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting

April 13, 2023

New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma

March 21, 2023

Natera Announces Commercial Payor Coverage for Signatera™

March 1, 2023

Natera Reports Fourth Quarter and Full Year 2022 Financial Results

February 27, 2023

Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

February 22, 2023

Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call

February 20, 2023

Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer

February 15, 2023

New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease

February 1, 2023

New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023

January 18, 2023

Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer

January 16, 2023

Natera to Webcast Live Presentation at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Calls in 2023

Decks in 2023